Therefore, specific inhibition of only APP β-cleavage, but not complete inhibition of BACE1 function, may be the most appropriate therapy to normalize the increased APP-directed BACE1 activity seen in AD patients. This evidence concerns the gene BACE1 and Alzheimer disease.